Authorization criteria are written per product and per indication, never per molecule. Because this product carries one approved use, glycemic control in type 2 diabetes, the reviewer applies diabetes criteria: a documented diagnosis, laboratory values and treatment history. A weight-management request runs against a different criteria document and, in most cases, a different product entirely.
Establish which document governs before anything is submitted
Ambetter plans are sold state by state under Centene, and the pharmacy benefit is administered against a drug list that belongs to that state plan and that plan year. Two documents matter. One is the drug list itself, which says whether the product is covered and whether it carries an authorization requirement. The other is the criteria document behind that requirement, which says what evidence the reviewer will look for.
Both carry an effective date, and both can be superseded mid-year. A criteria document found through a general search may belong to another state’s plan or to a prior version. The document number and the effective date printed on the page are the only reliable way to confirm the right one is being used, and submitting against the wrong version is the most common reason a request comes back asking for more information.
Diabetes criteria ask diabetes questions
The Mounjaro label describes an adjunct to diet and exercise for improving glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. Tirzepatide acts at both the GIP and GLP-1 receptors, and its clinical development for glycemic control ran separately from the obesity program that produced the weight-management brand. The plan’s review follows the label, not the pharmacology.
In practice that means a reviewer expects a recorded type 2 diabetes diagnosis with a date, recent glycemic laboratory values, and a picture of what has already been tried. Weight, body mass index and lifestyle history may appear in the record, but on this pathway they are context rather than the argument. Requests that lead with weight-related evidence for a diabetes-indicated product read as off-label to whoever opens the file.
See also: Monitoring Key Identifiers
What the submitted file has to carry
| Element | Where it comes from | Why requests stall on it |
|---|---|---|
| Product, strength and quantity | The prescription itself | Written for the sibling brand the plan does not list |
| Diagnosis and date established | The clinical record | Diagnosis exists in the chart but not on the request |
| Glycemic laboratory values | Dated results, not recollection | Results ordered but not back when the file was sent |
| Prior therapy and outcome | Chart notes and fill history | Duration and reason for stopping left blank |
| Governing criteria version | The state plan’s published policy | Superseded version, or another state’s document |
Specific thresholds inside those criteria differ by state plan, by product and by plan year, so the only version worth working from is the one published for that member. A threshold quoted secondhand is how prescribing offices end up submitting the same request twice.
Who submits, and what the clock allows
The prescribing office submits, normally through an electronic portal and occasionally by fax. Members cannot file the request themselves, though they can supply missing records and confirm the submission actually left the office rather than sitting in a queue. Under the federal rules covering marketplace coverage, an insurer must notify the member in writing and explain the reason within 15 days when prior authorization is being sought, within 30 days for services already received, and within 72 hours for urgent care situations.
Two habits shorten the wait. Get the reference number at submission, since without it nobody on a phone line can locate the file. And ask specifically whether anything was returned as incomplete, because a pending request and a request bounced for missing data look identical from outside the system.
Approval names a product and expires
An authorization attaches to the product it was written for and runs for a fixed term. Switching between the two tirzepatide brands generally requires a fresh request even when nothing clinical has changed, because the second brand has its own indication, its own place on the drug list and its own criteria. Members who assume approval follows the molecule find out at the pharmacy counter.
The off-label route is a separate process
When the treatment goal is weight rather than glycemic control, the honest path is usually the labeled weight-management product, which carries its own indications including moderate to severe obstructive sleep apnea in adults with obesity. Asking a plan to authorize a diabetes product for weight is an exception request, not a standard authorization, and it needs the prescriber to argue the case explicitly rather than resubmit the same form.
Pricing the wait
Published self-pay prices in this category come from several kinds of source, and they are easier to read as a group than one at a time. Eli Lilly posts a branded figure through LillyDirect, and clinics such as Henry Meds, PlushCare and HealthRX maintain their own Mounjaro pages, each bundling product, consultation and shipping differently. None of them is the default answer; they are points on a range.
Decisions take days in the best case and weeks in ordinary ones, and current obesity pharmacotherapy guidance treats continuity of therapy as part of the treatment rather than an optional extra. Cash pricing is therefore worth understanding before it is needed, not after.
Manufacturer channels publish figures for the branded products. Supervised telehealth practices, among them LifeMD, Hims and Hers and FormBlends, publish monthly figures for compounded semaglutide or tirzepatide. A quoted number settles very little by itself, because what is included depends on the provider behind it: who prescribes, which pharmacy fills, and whether the consultation and shipping sit inside the price. Compounded preparations are not FDA-approved and have not been reviewed by the agency for safety, effectiveness or manufacturing quality.
Frequently asked questions
Can a member start the authorization themselves?
No. It has to come from the prescribing office because it draws on the clinical record and the prescriber’s judgment. A member can send in missing records, confirm the plan and member identifiers are right, and call to verify the file arrived, which is often the difference between a two week wait and a six week one.
Does approval mean a low copay?
No. Authorization decides whether the plan pays at all. What the member pays is set separately by the drug’s placement on the list and by the plan’s deductible and cost sharing, so an approved product can still carry a large share of cost. Ask both questions rather than assuming one answers the other.
What is the difference between an exception and an appeal?
An exception asks the plan to cover something outside its normal rules, such as a drug that is not on the list or a use outside the label. An appeal challenges a decision the plan already made. They start in different places, and filing the wrong one restarts the clock.
Does authorization cover every dose in a titration?
Not automatically. Some approvals name a strength and quantity, so a dose increase can require an update. Asking at approval whether the authorization spans the full titration range avoids a rejection at the counter in the week the dose changes.
